Last Updated: April 13, 2015
German Ambassador to India
Updated: March, 2015
SECTORAL REPORT | October, 2014
The Biotech industry in India has been able to successfully position itself to capitalise on the unfolding global biologics opportunity by attracting talent with advanced technical skill-sets.
The biotechnology sector of India is highly innovative and is on a high growth trajectory. The sector, with its immense growth potential, will continue to play a more significant role as an innovative manufacturing hub. The sector is one of the most significant sectors in enhancing India's global profile as well as contributing to the growth of the economy. This sector is directly or indirectly related to the health as well as the agricultural sector of India.
India is among the top 12 biotech destinations in the world and is the largest producer of recombinant Hepatitis B vaccine. Out of the top 10 biotech companies in India (by revenue), six focus their expertise in bio-pharmaceuticals and four specialise in agri-biotech.
India had recently overtaken Canada to emerge as the fourth largest country to grow biotech or genetically modified (GM) crops, as farmers here planted Bt cotton in about 11 million hectares. The global acreages under GM crops increased to 175.2 million hectares in 2013, about five million hectares more than the previous year.
India also has no dearth of talent in this sector, as a number of institutions, both government and autonomous, provide the necessary opportunities for the student seeking to obtain a degree in this sector. Also, the Government of India has provided adequate scope to this sector by providing facilities for research and development (R&D) in the field of biotechnology.
The Indian biotech industry holds about 2 per cent share of the global biotech industry.
The Indian biotechnology sector is expected to grow from the current US$ 5-7 billion to US$ 100 billion by 2025 by doubling the growth rate of this sector from 15 percent to 30 percent, according to the Association of Biotechnology Led Enterprises (ABLE).
The high demand for different biotech products has also opened up scope for the foreign companies to set up bases and reap great profits. The biotechnology industry in India, comprising about 400 companies, has grown three-fold in the last five years to reach US$ 4 billion in FY 13. Growing at an average rate of about 20 per cent, India's biotech industry comprising biopharmaceuticals, bioservices, bioagriculture, bioindustry and bioinformatics could reach the US$ 7 billion mark by FY 15.
Biopharma is the largest sector contributing about 62 per cent of the total revenue followed by bioservices (18 per cent), bioagri (15 per cent), bioindustry (four per cent), and bioinformatics contributing (one per cent).
India has emerged as a leading destination for clinical trials, contract research and manufacturing activities owing to the growth in the bioservices sector, which accounts for revenue generation worth about US$ 636.73 million.
India's biotech sector has attracted significant amount of attention over the past two decades. Several global companies have aggressively joined hands with Indian companies due to India's strong generic biotechnology potential. Some of the recent investments in this sector are as follows:
A Network of Technology Centres and promotion of start-ups by SIDBI are among few of the steps taken by the government to promote innovation and entrepreneurship in agro industry proposed by the MSME Ministry in a new scheme. The scheme follows the announcement of a Rs 200 crore (US$ 31.99 million) fund by Finance Minister Mr Arun Jaitley in his Budget speech this year for promoting innovation and entrepreneurship in agro industry.
The Government of India has taken a lot of initiatives to improve the biotechnology sector in the country as well as offer enough scope for research in this field. The Department of Biotechnology (DBT) along with other government funded institutions such as National Biotechnology Board (NBTB) and many other autonomous bodies representing the biotechnology sector, are actively working together so as to project India as a global hub for biotech research and business excellence. Some of the recent major initiatives are as follows:
With the country offering numerous comparative advantages in terms of R&D facilities, knowledge, skills, and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.
India currently has a marginal share in the global market for industrial enzymes that is estimated to reach about US$ 4.4 billion by 2015. Hence, there is an opportunity in focused R&D and knowledge-based innovation in the field of industrial enzymes, which can innovatively replace polluting chemical processes into eco-friendly processes that also deliver environmental sustainability. Another interesting field of study is the area of bio-markers and companion diagnostics, which will enable to optimise the benefits of biotech drugs.
The growth in gross domestic product (GDP) over the next decade will expand the domestic market and Indians will be able to afford healthcare products, and demand for food commodities and energy will grow too. Presently, many countries are looking forward to invest in the Indian biotechnology sector.
India has all the ingredients to become a global leader in affordable healthcare. If there is an annual investment of US$ 4.01 billion to US$ 5.02 billion in the next five years, the biotech industry can grow to US$ 100 billion by 2025, with a 25 per cent return on investment, and set a growth rate of 30 per cent year-on-year.
With all the support, government initiatives and determination to excel, India can soon attain global leadership in providing affordable healthcare and innovative medicines, quality food and feed for all.
Exchange Rate Used: INR 1 = US$ 0.016 as on March 20, 2015
References: Press Information Bureau (PIB), Media Reports and Press Releases, Department of Industrial Policy and Promotion (DIPP), Department of Biotechnology.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
The Indian biotechnology sector is expected to clock US$ 10 billion in revenue by 2015 on the back of emerging opportunities from around the world.